2 weeks Ago By ABMN Staff
Federated Hermes Inc. lowered its position in shares of Dynavax Technologies Co. ( NASDAQ:DVAX – Free Report ) by 99.
9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,000 shares of the biopharmaceutical company’s stock after selling 5,600,200 shares during the quarter. Federated Hermes Inc.
’s holdings in Dynavax Technologies were worth $102,000 as of its most recent filing with the SEC. Several other hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP purchased a new position in Dynavax Technologies during the third quarter worth about $758,000.
Barclays PLC increased its position in Dynavax Technologies by 137.4% during the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock worth $3,371,000 after purchasing an additional 175,118 shares during the period.
SkyView Investment Advisors LLC purchased a new position in shares of Dynavax Technologies during the 3rd quarter worth approximately $127,000. Sanctuary Advisors LLC lifted its holdings in shares of Dynavax Technologies by 9.1% in the 3rd quarter.
Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 1,484 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Dynavax Technologies in the third quarter valued at approximately $89,000. Institutional investors and hedge funds own 96.
96% of the company’s stock. Dynavax Technologies Trading Down 3.3 % NASDAQ:DVAX opened at $10.
30 on Friday. The company has a market capitalization of $1.28 billion, a PE ratio of 57.
21 and a beta of 1.26. Dynavax Technologies Co.
has a 52-week low of $9.74 and a 52-week high of $14.63.
The stock has a fifty day simple moving average of $12.98 and a 200-day simple moving average of $12.56.
The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.
33. Wall Street Analyst Weigh In Several research firms have issued reports on DVAX. HC Wainwright reiterated a “buy” rating and issued a $31.
00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th.
William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $12.00 to $10.
00 and set a “sell” rating on the stock in a research report on Thursday. Get Our Latest Research Report on DVAX About Dynavax Technologies ( Free Report ) Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
See Also Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. ( NASDAQ:DVAX – Free Report ).
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter ..
